{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002100","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.447895+00:00","generated_at":"2026-06-18T23:10:56.779224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protalix FY2022 net loss narrows to $14.9M; CHMP positive opinion for PRX-102; FDA PDUFA May 9","bullets":["Net loss of $14.9M ($0.31/share) vs $27.6M ($0.62/share) in FY2021; revenue from goods up 51% to $25.3M.","EMA CHMP adopted positive opinion recommending marketing authorization for PRX-102 (pegunigalsidase alfa) for Fabry disease; EC decision expected May 2023.","FDA accepted resubmitted BLA for PRX-102 with PDUFA action date of May 9, 2023; milestone payment from Chiesi if approved.","Cash and equivalents $22.2M at Dec 31, 2022; voluntary delisting from Tel Aviv Stock Exchange effective March 22, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002100","json":"https://secwatch.observer/filing/0001558370-23-002100.json","markdown":"https://secwatch.observer/filing/0001558370-23-002100.md","text":"https://secwatch.observer/filing/0001558370-23-002100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023002100/0001558370-23-002100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023002100/plx-20230227x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:10:56.779224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"640e7b49692e7b4a355a9a671aab662678d4d42a","claim":"Protalix BioTherapeutics, Inc. reported the fiscal year ended December 31, 2022 results: revenue $25.3 million.","evidence_excerpt":"Committee. Financial Results For the year ended December 31, 2022, compared to the year ended December 31, 2021 ● The Company recorded revenues from selling goods of $25.3 million for the year ended December 31, 2022, an increase of $8.6 million, or 51%, compared to revenues of $16.7 million for the year ended December 31, 2021. The increase resulted from","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023002100/0001558370-23-002100-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$25.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}